Publications
Publications
- August 2013 (Revised October 2013)
- HBS Case Collection
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Abstract
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.
Keywords
MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Citation
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)